EU co-legislators reached a provisional agreement to reform EU pharmaceutical legislation, aiming to enhance competitiveness, innovation, and supply security. The agreement includes measures such as regulatory data protection, market exclusivity periods for different conditions, and promoting the earlier entry of generic and biosimilar products. The deal also covers combating antimicrobial resistance with new measures, improving EMA's processes, and ensuring a competitive regulatory framework. The core focus is on promoting innovation, increasing access to medication, and addressing antimicrobial resistance while maintaining a competitive landscape in the EU pharmaceutical sector.